Therapeutic targeting of ligands by CTLA4-Ig fusion proteins (Abatacept) or blocking CTLA4 with antibodies (e.g. Ipilimumab) have been used in autoimmunity and cancer to inhibit or invigorate CD28 signals, respectively. The gene discussed is CTLA4; the disease is cancer.